Viewpoint on the complex challenges of HIV vaccine development

Despite substantial progress in understanding and treating HIV/AIDS, existing tools have not effectively controlled the epidemic, and the potential threat of resurgence looms as the largest cohort of young people in history enters early adulthood. Treatment alone will not end the epidemic. The International AIDS Society – Lancet Commission recommends that global treatment efforts should be complemented with stronger investments in primary prevention, including research to accelerate the development of a preventive vaccine. Indeed, even a partially effective vaccine could help to change the course of the HIV epidemic and have a substantial public health impact.

In this viewpoint published in The Lancet, key stakeholders look into the challenges of developing an HIV vaccine from development to marketing.